RESEARCH & DEVELOPMENT

INNOVATION IS OUR DRIVING FORCE

Innovation is at the heart of our R&D. Our global team of researchers and scientists is striving to push the boundaries of science to bring transformative therapies, better health and a brighter future to patients worldwide.

We are focused on addressing critical unmet needs in cancer immunotherapy — cancer treatments using Car-T, DC Vaccine, or γδ T cell therapies.

CAR-T treatment

CAR-T Treatment

CAR-T treatment is a complex and personalised treatment for cancer. With CAR-T treatment, cell-killing T-cells are removed from the body and engineered to recognise the cancer target. After the edited T-cells (CAR-Ts) are reintroduced to the patient, they multiply and attack the targeted cancer cell.

DC (Dendritic Cells) Vaccine therapy

DC (Dendritic Cells) Vaccine therapy is a widely known type of immune cell therapy for tumours. Dendritic cells (DCs) are a type of antigen-presenting cells that play an important role in adaptive immune system. Their main function is to process antigen material (cancer in this case) and present to the T cells of the immune system. With implementation of dendritic cells, DC Vaccine therapy proliferates cancer killing cells (CTL – Cytotoxic T Cell) to target a specific type of cancer.

DC (Dendritic Cells) Vaccine therapy

We foster an ecosystem of innovation by engaging in individualized partnerships, catalyzing cross-industry collaboration, and supporting promising early researchers. Together, with our ecosystem we are optimizing our pipeline, enhancing ca-abilities and advancing new treatment options for patients.

R&D PIPELINE

Pre-Clinical

Clinical Phase I

Clinical Phase II

Clinical Phase III

PENAO
DC Vaccine Therapy (In conjunction with Dendrix Inc)
p38MAPK (Spinal Injury)
Close Menu